FDA approves Exforge HCT for treatment of hypertension

June 2009
Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p59
The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to the antihypertensive drug Exforge HCT for patients with moderate-to-severe hypertension.


Related Articles

  • The year's new drugs. Rodman, Morton J. // RN;Jan80, Vol. 43 Issue 1, p97 

    Provides information on several drugs approved by the United States Food and Drug Administration in 1979. Pain relievers; Prompt relief for menstrual symptoms; Antihypertensive diuretic.

  • Olmesartan label to warn of sprue-like side effects.  // Reactions Weekly;7/13/2013, Issue 1461, p4 

    The article reports that the labels for the antihypertensive olmesartan medoxomil which are to be updated by the U.S. Food and Durgs Administration (FDA) to warn the risk of sprue-like enteropathy.

  • Fixed combination for hypertension.  // Modern Medicine;Sep95, Vol. 63 Issue 9, p27 

    Reports that the US Food and Drug Administration has approved Amlodipine/benazil HCL capsules, the first class of a new class of fixed combination antihypertensive. Availability; Addition of benazepril.

  • Two diabetes trials leave Benicar at a crossroads.  // Reactions Weekly;6/19/2010, Issue 1306, p2 

    The article deals with the safety review of the antihypertensive medication, olmesartan, being conducted by the U.S. Food and Drug Administration in June 2010.

  • Angiotensin receptor blockers and cancer: safety review.  // WHO Drug Information;2010, Vol. 24 Issue 4, p301 

    The article discusses a 2010 decision which the U.S. Food and Drug Administration made to conduct a review of the class of medications known as angiotensin receptor blockers after a study was published which suggested the medications may be associated with a small increased risk of cancer.

  • Prescription Pattern of The Drugs Among Pregnant Inpatients In Tertiary Care Hospital. Farooq, Mohammed Omar; Reddy, Suneel Kumar; Prasada, M. S. Raghu; Nagraj, Srujana Ambati; Karupakula, Samanvita; Natarajan, Deepthi K. // Journal of Pharmacy Research;Jul2014, Vol. 8 Issue 7, p981 

    Objectives: To know the prescription pattern of the drugs among pregnant inpatients in tertiary care hospital. Methods: A total of 125 patients were included in this prospective study and relevant details were obtained from the patients and case sheets. The current drug treatment details as an...

  • Aliskiren-HCT cleared for treatment of hypertension. Raible, Eric; Bakris, George L. // Cardiology Today;Mar2008, Vol. 11 Issue 3, p3 

    The article reports that the U.S. Food and Drug Administration (FDA) has cleared a direct renin inhibitor antihypertensive drug from Novartis known as aliskiren-hydrochlorothiazide (HCT). Based on the article, the drug is the first approved medication for hypertension to combine two therapies....

  • FDA officials disagree about the safety of ARBs. Mccarthy, Mike // BMJ: British Medical Journal;6/15/2013, Vol. 346 Issue 7912, p6 

    The article reports on the debate between the U.S. Food and Drug Administration (FDA) and Thomas A Marciniak, a senior safety reviewer at the FDA, over the availability of adequate evidence to suggest an association between angiotensin receptor blockers (ARBs) and an increased risk of lung cancer.

  • FDA Drug Approvals.  // Geriatrics;Mar2005, Vol. 60 Issue 3, p22 

    The article reports on drugs which are approved by the U.S. Food and Drug Administration. Eszopiclone is a non-benzodiazepine hypnotic for treatment of insomnia. Eszopiclone interacts with gammaamino butyric acid receptors. Eszopiclone's effect on sleep onset may be reduced if taken with or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics